Prof René-Olivier Mirimanoff speaks about his research into the use of temozolomide and radiotherapy to treat glioblastoma brain tumours and outlines further developments he expects to see in this area. Prof Mirimanoff also discusses a trial he working on which is looking at personalising treatment according to MGMT expression. Half of glioblastoma brain tumour patients have a methylation of the gene promoter of MGMT which inhibits MGMT production. These patients are more sensitive to radiotherapy and chemotherapy and should therefore be treated as separate subgroups and their treatment should vary accordingly.